论文部分内容阅读
呼吸窘迫综合征(RDS)是新生儿的常见的重症疾病。它是因肺不成熟、缺乏肺表面活性物质(S)所致的肺功能不全。在抢救本症重症病例时常导致严重的并发症。如由于高压的人工换气疗法及高浓度氧气疗法,使肺泡破裂发生气胸、间质性肺气肿、氧中毒等。对RDS 使用人工肺表面活性物质(S)在生后数小时内注入气管内,可明显改善肺功能。RDS 是一种综合征,在循环系统,肾脏不成熟基础上以肺不成熟(缺乏肺表面活性物质、肺泡上皮细胞通透性过强)为主要表现的病变。作者对重症RDS,其出生时体重500～2500g 的96例进行了肺表面活性物质的分析,结果以缺乏S 为主者76例(76/96);症候性动脉导管未闭(PDA)复发者15例(15/96);胎
Respiratory distress syndrome (RDS) is a common severe disease in newborns. It is due to immature lungs, the lack of lung surfactant (S) caused by pulmonary insufficiency. Severe cases of salvage often lead to serious complications. Such as due to high-pressure artificial ventilation therapy and high concentrations of oxygen therapy, pneumothorax rupture pneumothorax, interstitial emphysema, oxygen poisoning. Infusion of artificial pulmonary surfactant (S) into the trachea within a few hours after birth on RDS can significantly improve lung function. RDS is a syndrome characterized mainly by the immaturity of the lung (lacks lung surfactant and alveolar epithelial cell permeability) on the basis of the circulatory system and immature kidneys. The author of the analysis of 96 cases of severe RDS, birth weight 500 ~ 2500g of pulmonary surfactant, the results of the lack of S mainly 76 cases (76/96); patients with recurrent patent ductus arteriosus (PDA) 15 cases (15/96); fetal